Literature DB >> 7471607

Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide.

L H Wang, C S Lee, B L Majeske, T C Marbury.   

Abstract

The hemodialyzability of cyclophosphamide was investigated in four patients on long-term hemodialysis. Cyclophosphamide 100 mg was given intravenously over 10 min before hemodialysis. Blood and dialysate samples were collected periodically during the 4 hr dialysis and measured by gas-liquid chromatography (GLC) for cyclophosphamide. Dialysis clearance calculated by arterial-venous difference and actual drug recovery in dialysate averaged 104 ml/min, which is in the range of the metabolic clearance of 95 ml/min for the drug. The extraction efficiency of the hollow-fiber dialyzers averaged 40% for plasma and red blood cell (RBC) samples. A mean of 37% of the administered dose of cyclophosphamide was removed during hemodialysis. The half-life (t 1/2) of the beta phase was 3.3 hr in our patients during hemodialysis, a 49% reduction of the 6.5 hr to t 1/2 reported in uremic patients. Because of the reduction in elimination t 1/2, larger dialysis clearance than metabolic clearance, high extraction efficiency, and significant drug removal during dialysis, we conclude that cyclophosphamide is dialyzable.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7471607     DOI: 10.1038/clpt.1981.50

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors:  Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Predicative calculation of the efficiency of hemodialysis or hemoperfusion for the removal of drugs from the body.

Authors:  H H Wellhöner
Journal:  Arch Toxicol       Date:  1985-01       Impact factor: 5.153

Review 3.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 4.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

5.  Disposition and removal of metronidazole in patients undergoing haemodialysis.

Authors:  A Somogyi; C Kong; J Sabto; F W Gurr; W J Spicer; A J McLean
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

8.  Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats.

Authors:  Jianxiu Zhai; Feng Zhang; Shouhong Gao; Li Chen; Ge Feng; Jun Yin; Wansheng Chen
Journal:  Molecules       Date:  2017-08-08       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.